Wenhua Wang
Fellow Scientist Regeneron
Dr. Wenhua Wang is a Fellow Scientist in the Drug Product Development and Technology Department at Regeneron Pharmaceuticals, Inc., where she leads a team advancing formulation development and technology transfer to GMP manufacturing for therapeutic antibodies and antibody–drug conjugates (ADCs). Previously, she worked at Genentech and Bristol-Myers Squibb, specializing in drug product formulation and analytical method development. Dr. Wang earned her Ph.D. in Biophysics from the University of Rochester. Her research focuses on protein structural characterization, protein–protein interactions, biomolecular phase separation, photo stability of ADCs and applying machine learning to assess antibody developability.
Seminars
As the ADC field shifts to novel payload mechanisms and more complex ADC design to deliver meaningful patient impact, quality characterization and control strategies need to be adapted and updated to keep up with the rate of ADC innovation.
Join this workshop led by big pharma leaders and members of the IQ consortium to investigate best approaches for non-cytotoxic and non-traditional ADC control strategies.
Workshop highlights include:
- Defining the control strategy for noncytotoxic bioconjugates including AOCs and antibody–peptide conjugates across CQAs, release testing, and stability
- Comparing control strategies for noncytotoxic versus cytotoxic bioconjugates, highlighting differences in potency assays, impurity profiles, and safety controls
- Applying patient centric quality control to non-cytotoxic bioconjugates by linking specifications to clinical relevance
